-
| ISIN | None |
|---|---|
| Industry | Biotechnology |
| Sector | Healthcare |
| CurrencyCode | USD |
| Exchange | NASDAQ |
| Beta | nan |
|---|---|
| Dividend Yield | 0.0% |
| Target Price | 24.67 |
| PE Ratio | None |
| Market Cap | 179M |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ANTX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024